NASDAQREGN

Business

Regeneron, Sanofi post mixed data for Dupixent trials (NASDAQ:REGN)

moxumbic Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) on Wednesday announced that a Phase 3 trial for their blockbuster asthma therapy Dupixent…

Read More »
Back to top button